Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P46977
UPID:
STT3A_HUMAN
Alternative names:
B5; Integral membrane protein 1; Transmembrane protein TMC
Alternative UPACC:
P46977; B4DJ24; E9PNQ1; Q86XU9; Q8TE35; Q8WUB4
Background:
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3A, also known as B5, Integral membrane protein 1, and Transmembrane protein TMC, plays a pivotal role in protein N-glycosylation. It acts as the catalytic subunit of the oligosaccharyl transferase (OST) complex, facilitating the transfer of glycan to nascent polypeptide chains within the endoplasmic reticulum. This process is essential for proper protein folding and function.
Therapeutic significance:
STT3A's involvement in congenital disorders of glycosylation, including both autosomal recessive and dominant forms, underscores its clinical importance. These disorders manifest in a wide array of symptoms, from developmental defects to immunodeficiency, highlighting the protein's potential as a target for therapeutic intervention.